Organon & Co.
NYSE:OGNDrug Manufacturers - General
+$0.01 today
- Market cap
- $3.66B
- Beta
- 1.54
- P/E (TTM)
- 14.2
- EPS (TTM)
- $0.94
- Dividend yield
- 0.60%
Volume 3.90M
Average 8.57M
OGN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Organon & Co.NYSE: OGN
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization dips below year-ago levels
Q3 FY2026 depreciation & amortization of $82M fell 10.9% year over year, behind the +0.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.5% from the prior quarter. Over 3 fiscal years it compounded at +19.4% a year.
Context
- Depreciation & amortization amounted to 5.8% of revenue in FY2025, up 1.5 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -10.9% toward the trailing-twelve-month pace of +0.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 361M USD
- Year-over-year change
- +30.3%
- 4-year CAGR
- +16.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 361M | +30.3% |
| FY2024 | 2024-12-31 | 277M | +17.4% |
| FY2023 | 2023-12-31 | 236M | +11.3% |
| FY2022 | 2022-12-31 | 212M | +8.7% |
| FY2021 | 2021-12-31 | 195M | — |
Depreciation & Amortization vs competitors
How OGN compares with its peers on the latest reported figures
- OGN's LTM Sep 2026 depreciation & amortization of $344M is the highest of the 10 companies compared; the peer median is $25.34M.
- Its year-over-year change of +0.6% is the 6th highest of 10, against a peer median of +3.1%.
- Depreciation & amortization amounts to 5.6% of revenue for OGN, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $344M | +0.6% | +19.4% | 5.6% | |
| LTM Mar 2026 | $143.16M | -22.5% | -12.0% | 2.6% | |
| LTM Feb 2026 | $113.28M | -37.8% | -2.0% | 9.6% | |
| LTM Mar 2026 | $50.58M | +19.3% | +11.7% | 3.4% | |
| LTM Mar 2026 | $31.92M | -1.4% | +22.9% | 5.7% | |
| LTM Jun 2026 | $25.34M | +6.1% | +2.7% | 2.6% | |
| LTM Sep 2026 | $23.78M | +3.1% | -15.1% | 1.2% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $23.36M | +11.8% | +10.5% | 1.6% |
| LTM Jun 2026 | $19.38M | -0.5% | +50.7% | 6.2% | |
| LTM Jun 2026 | $2.15M | +104.9% | +106.0% | 1.3% | |
| Peer median (excluding OGN) | $25.34M | +3.1% | +10.5% | 2.6% | |
Competitors are the stored peer set for OGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.3B | 6.17B | 6.26B | 6.4B | 6.22B |
| Cost of Revenue | 2.38B | 2.29B | 2.52B | 2.69B | 2.85B |
| Gross Profit | 3.92B | 3.88B | 3.75B | 3.72B | 3.36B |
| Gross Margin | 62.2% | 62.8% | 59.8% | 58.0% | 54.1% |
| Research & Development | 443M | 471M | 528M | 469M | 366M |
| Selling, General & Admin | 1.67B | 1.7B | 1.89B | 1.76B | 1.71B |
| Operating Expenses | 2.01B | 2.18B | 2.42B | 2.23B | 2.09B |
| Depreciation & Amortization | 195M | 212M | 236M | 277M | 361M |
| EBITDA | 1.98B | 1.76B | 1.44B | 1.6B | 1.29B |
| EBITDA Margin | 31.4% | 28.4% | 22.9% | 25.1% | 20.8% |
| Operating Income | 1.92B | 1.71B | 1.33B | 1.49B | 1.29B |
| Operating Margin | 30.4% | 27.6% | 21.2% | 23.2% | 20.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 258M | 422M | 527M | 520M | 504M |
| Other Income / Expenses | (386M) | (583M) | (654M) | (679M) | (860M) |
| Income Before Tax | 1.53B | 1.12B | 673M | 807M | 425M |
| Pre-Tax Margin | 24.3% | 18.2% | 10.7% | 12.6% | 6.8% |
| Income Tax Expense | 178M | 205M | (350M) | (57M) | 238M |
| Net Income | 1.35B | 917M | 1.02B | 864M | 187M |
| Net Margin | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% |
| EPS (Basic) | 5.33 | 3.61 | 4.01 | 3.36 | 0.72 |
| EPS (Diluted) | 5.33 | 3.59 | 3.99 | 3.33 | 0.72 |
| Weighted Avg Shares | 253.55M | 254.08M | 255.24M | 257.05M | 259.5M |
| Weighted Avg Shares (Diluted) | 253.55M | 255.17M | 256.27M | 259.15M | 260.76M |
Organon & Co.
NYSE:OGN
Intrinsic Alpha fair value
Locked
Current Price
$13.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.